Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Cash from Financing Activities (2020 - 2025)

Firefly Neuroscience has reported Cash from Financing Activities over the past 9 years, most recently at $250000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $250000.0 for Q4 2025, down 86.66% from a year ago — trailing twelve months through Dec 2025 was $11.6 million (up 84.46% YoY), and the annual figure for FY2025 was $11.6 million, up 84.46%.
  • Cash from Financing Activities for Q4 2025 was $250000.0 at Firefly Neuroscience, up from -$19000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AIFF hit a ceiling of $10.3 million in Q1 2025 and a floor of -$87245.0 in Q2 2023.
  • Median Cash from Financing Activities over the past 5 years was $1.0 million (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 88401.84% in 2021 and later crashed 1139.62% in 2023.
  • Firefly Neuroscience's Cash from Financing Activities stood at $8.9 million in 2021, then tumbled by 95.2% to $425000.0 in 2022, then surged by 404.94% to $2.1 million in 2023, then decreased by 12.67% to $1.9 million in 2024, then crashed by 86.66% to $250000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $250000.0 (Q4 2025), -$19000.0 (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.